EUCTR2010-022808-40-IT进行中（未招募）不适用
A fase II, randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients - ND
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点开始时间: 2011年2月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subject is willing and able to give written informed consent for participation in the study 2) Subject is able (in the investigator’s opinion) and willing to comply with all study requirements. 3) Age between 18 and 80 years 4) Affected by ALS, either of definite, probable or possible category according to the El Escorial revised criteria or by primary lateral sclerosis, according to Pringle’s criteria; 5) Affected of spasticity, equal or above 1 in the Ashworth Scale for spasticity in 2 or more muscle groups; 6) Who will judge spasticity a relevant cause of movements impairment 7) Subject has spasticity due to MND of at least three months duration, which is not wholly relieved with current anti-spasticity therapy, and which is expected to remain stable for the duration of the study. 8) Subject fulfils at least one of the two criteria below. Subject must be either: - Currently established on a regular dose of anti-spasticity therapy, or - Previously tried and failed, or could not tolerate suitable anti-spasticity therapy 9) Subject is currently receiving a stable regimen (for at least 30 days prior to study entry) of all medications that may have an effect on spasticity and is willing to maintain this for the duration of the study. 10) Stabilization of factors affecting spasticity: any physiotherapy regimen or medication likely to affect spasticity will be optimised before the study and not altered in the 3 weeks before start of treatment 11) Subject is willing to allow his or her primary care physician and consultant, if appropriate, to be notified of participation in the study. 12) Subject is willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable. Additional inclusion Criteria to be met at baseline 1. Subjects have registered spasticity NRS scores via the personal clinical diary over the 6 days (day 2 to Aday 7) Subjects who are non-compliant will be deemed ineligible to continue. 2. The subject has not had the introduction of any new anti-spasticity medication or any alteration to the dosage of anti-spasticity medication during week 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject’s level of spasticity. 2. Subjects receiving Botulinum Toxin during the preceding six months. 3. bedridden and tracheotomised patients. 4. Fixed-tendon contractures 5. Severe cognitive impairment 6. Currently using or has used cannabis, cannabinoid-based medications or Acomplia (Rimonabant) within 30 days of study entry and unwilling to abstain for the duration of the study. 7. Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition. 8. Any known or suspected history of a diagnosed dependence disorder, current heavy alcohol consumption, current use of an illicit drug or current non-prescribed use of any prescription drug. 9. Subjects with poorly controlled epilepsy or recurrent seizures (Subjects who have had one or more fits in the year prior to Visit 1 will be excluded). 10. Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP. 11. Subject has experienced myocardial infarction or clinically relevant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the subject at risk of a clinically relevant arrhythmia or myocardial infarction. 12. Subject has a diastolic blood pressure of <50 mmHg or >105 mmHg (when measured in a sitting position at rest for five minutes) or a postural drop in the systolic blood pressure of greater than 20 mmHg at Visit 1. 13. Personal history suggestive of relevant impaired renal or hepatic function at Visit 1. 14. Female subjects of child bearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter. 15. Female subject who is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter 16. Subjects who have received any IMP within the 8 weeks before Visit 1. 17. Any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the result of the study, or the subject’s ability to participate in the study 18. Following a physical examination, the subject has any abnormalities that, in the opinion of the investigator, would prevent them from safely participating in the study. 19. Unwilling to abstain from donation of blood during the study. 20. Patients will be asked not to drive while they will be receiving medication and, if unable to comply, will be excluded
研究者
相似试验
已完成
不适用
Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes MellitusPER-132-08TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
进行中（未招募）
2 期
A Study of Oral Azacitidine or Placebo with Best Supportive Care as Maintenance Therapy in Japanese Subjects with Acute Myeloid Leukemia in Complete RemissioAcute Myeloid LeukemiaJPRN-jRCT2011210063Hayakawa Jin66
进行中（未招募）
1 期
A study comparing the combination of the best supportive care plus E7080 versus best supportive care alone, in patients with advanced lung cancer or lung cancer that has spread, who have been previously treated, unsuccessfully, with at least 2 different treatmentsocally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 15.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002347-10-GBEisai Inc.135
进行中（未招募）
不适用
A study comparing the combination of the best supportive care plus E7080 versus best supportive care alone, in patients with advanced lung cancer or lung cancer that has spread, who have been previously treated, unsuccessfully, with at least 2 different treatmentsocally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002347-10-CZEisai Inc.135
进行中（未招募）
不适用
A clinical study to test the efficacy of a new product (TNF-Kinoid) in patients with Rheumatoid Arthritis in whom treatment with methotrexate is not working anymoreActive Rheumatoid ArthritisMedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001999-38-PLeovacs SA140